@article {Hou164, author = {Si-Yuan Hou and Xing-Huo Feng and Chang-Liang Lin and Yong-Feng Tan}, title = {Efficacy of Xuebijing for coagulopathy in patients with sepsis}, volume = {36}, number = {2}, pages = {164--169}, year = {2015}, doi = {10.15537/smj.2015.2.9895}, publisher = {Saudi Medical Journal}, abstract = {Objectives: To provide evidence of the clinical efficacy of Xuebijing (XBJ) on blood coagulation in patients with sepsis.Methods: We conducted this meta-analysis in The People{\textquoteright}s Hospital of Liaoning Province, Shenyang, China between December 2013 and May 2014. We searched a number of databases for relevant randomized controlled trials (RCTs) published before December 2013 using the keywords {\textquoteleft}Xuebijing{\textquoteright}, {\textquoteleft}coagulation{\textquoteright} and {\textquoteleft}sepsis{\textquoteright}. Statistical analysis was performed with Review Manager 5.2 from the Cochrane Collaboration.Results: Fourteen RCTs involving 867 patients were included. Compared with placebo, XBJ injection significantly improved platelets (mean differences [MD] = 42.14, 95\% confidence interval [CI]: 22.42 - 61.86, p\<0.00001), shortened the activated partial thromboplastin time (MD = -4.81, 95\% CI: -7.86 - [-1.76], p=0.002), shortened the prothrombin time (MD = -2.33, 95\% CI: -4.15 - [-0.51], p=0.01), and shortened the thrombin time (MD = -2.05, 95\% CI: -3.52 - [-0.58], p=0.006). However, no significant difference was found between the XBJ injection and the placebo group for fibrinogen (MD = 0.21, 95\% CI: -0.38 - 0.81, p=0.48).Conclusion: Xuebijing injection may improve coagulopathy in patients with sepsis. High-quality and large sample clinical trials are needed for confirmation.}, issn = {0379-5284}, URL = {https://smj.org.sa/content/36/2/164}, eprint = {https://smj.org.sa/content/36/2/164.full.pdf}, journal = {Saudi Medical Journal} }